- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00764374
A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia
October 28, 2014 updated by: Astellas Pharma Inc
To examine the safety and efficacy of Z-338 (YM443) after long-term administration in patients with functional dyspepsia, and also to examine the pattern of long-term administration.
Study Overview
Study Type
Interventional
Enrollment (Actual)
412
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hokkaido, Japan
-
Kansai, Japan
-
Kantou, Japan
-
Kyushu, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 79 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patient showing at least one of the following 4 symptoms from more than 6 months before obtaining consent
- postprandial fullness
- early satiation
- upper abdominal pain
- upper abdominal discomfort
- Patient showing at least 2 of the 8 symptoms shown below repeatedly from 3 months before obtaining consent (At least one symptom of either postprandial fullness or early satiation should be included.)
Patient showing either postprandial fullness, bloating in the upper abdomen, or early satiation as the major complaint among the 8 symptoms shown below at the time of obtaining consent
- upper abdominal pain
- upper abdominal discomfort
- postprandial fullness
- bloating in the upper abdomen
- early satiation
- nausea
- vomiting
- belching
- Outpatient
Exclusion Criteria:
- Patient showing symptoms of organic disease (reflux esophagitis, erosion, ulceration, esophageal hiatal hernia, bleeding, malignant tumor, Barrett's esophagus) when upper gastrointestinal endoscopy is performed within 24 weeks before obtaining consent
- Patient showing heartburn within 12 weeks before obtaining consent
- Patient complicated by irritable bowel syndrome
- Patient complicated by diabetes mellitus requiring medication
- Patient complicated by severe anxiety disorder with some problems in interpersonal relationships or social life
- Patient complicated by depression (including suspected cases) or sleep disturbance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subject's global assessment
Time Frame: Every week
|
Every week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disappearance rate of symptoms
Time Frame: Every week
|
Every week
|
Laboratory tests, resting
Time Frame: At 0, 4, 12, 24, 36, 48 week
|
At 0, 4, 12, 24, 36, 48 week
|
12-lead ECG
Time Frame: At 0, 24 and 48 week
|
At 0, 24 and 48 week
|
Adverse events
Time Frame: During treatment
|
During treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
December 1, 2009
Study Registration Dates
First Submitted
September 30, 2008
First Submitted That Met QC Criteria
October 1, 2008
First Posted (ESTIMATE)
October 2, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
October 29, 2014
Last Update Submitted That Met QC Criteria
October 28, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 443-CL-501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of
Clinical Trials on YM443
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncAstellas Pharma US, Inc.Completed
-
Astellas Pharma IncCompletedFunctional DyspepsiaUnited States